Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing next-generation precision medicines targeting FGFR biology. The news flow around TYRA, as reflected in its recent press releases, centers on clinical trial progress, scientific presentations, regulatory designations and corporate developments related to its FGFR-focused pipeline.
Investors and followers of TYRA news can expect updates on dabogratinib (formerly TYRA-300), the company’s lead oral FGFR3-selective inhibitor. Recent announcements include dosing the first patient in the SURF302 Phase 2 study for FGFR3-altered intermediate risk non-muscle invasive bladder cancer, dosing the first child in the BEACH301 Phase 2 study for pediatric achondroplasia, and plans to expand development into low-grade upper tract urothelial carcinoma through the SURF303 study. Tyra also reports interim proof-of-concept results in metastatic urothelial carcinoma and regulatory designations such as Orphan Drug Designation and Rare Pediatric Disease Designation for dabogratinib in achondroplasia.
News coverage further highlights progress in early-stage oncology programs TYRA-200 and TYRA-430, including enrollment and dosing in the SURF201 and SURF431 Phase 1 studies for intrahepatic cholangiocarcinoma, hepatocellular carcinoma and other FGFR-driven tumors. Tyra’s communications also describe scientific visibility events, such as a late-breaking poster on TYRA-300 preclinical data at ENDO 2025 and fireside chats or presentations at healthcare and biotechnology investor conferences.
In addition, Tyra Biosciences issues quarterly financial results press releases and Form 8-K filings that summarize research and development spending, cash runway expectations and key clinical milestones. Corporate news has included strengthening the leadership team with appointments in operations and regulatory affairs. For readers tracking TYRA, this news stream provides ongoing insight into the company’s clinical development timelines, scientific activities and corporate priorities in FGFR-targeted precision medicine.
Tyra Biosciences announced promising interim clinical data for TYRA-300, their investigational oral FGFR3-selective inhibitor, in treating metastatic urothelial cancer (mUC). In patients receiving ≥90mg daily doses, 6 out of 11 (54.5%) achieved confirmed partial response, with 100% disease control rate. The study included 41 heavily pre-treated patients, with 44% receiving ≥3 prior therapies. TYRA-300 demonstrated favorable safety results across all doses, showing infrequent FGFR2/FGFR1-associated toxicities. Only 4 serious adverse events (10%) were reported, with one dose-limiting toxicity of grade 3 diarrhea at 90mg daily.
Tyra Biosciences (Nasdaq: TYRA) announced it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to present interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). The data will be presented at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain. Dr. Gary Steinberg from Rush University Medical Center will join TYRA's management team for the presentation and Q&A. The webcast will be accessible through TYRA's investor relations website, with telephone participation available through pre-registration.
Tyra Biosciences (Nasdaq: TYRA) announced three abstracts for presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) in Barcelona, Spain, from October 23-25, 2024. The presentations include:
1. A late-breaking oral presentation on the preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301).
2. A poster on the preliminary pharmacokinetic and pharmacodynamic analysis of TYRA-300 from the SURF301 study.
3. A poster on the multicenter, open-label Phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations (SURF301).
The abstracts are embargoed until 00.01 hrs CEST on Friday, October 25, 2024.
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) biology, has announced its participation in the 2024 Cantor Global Healthcare Conference. CEO Todd Harris will engage in a fireside chat on September 17, 2024, at 9:45 am ET. The company's management will also conduct one-on-one meetings with investors during the event.
A live and archived webcast of the fireside chat will be accessible through the Investor section of TYRA's website. This participation underscores TYRA's commitment to engaging with the investment community and showcasing its progress in developing next-generation precision medicines targeting significant opportunities in FGFR biology.
Tyra Biosciences (Nasdaq: TYRA) has appointed Doug Warner, M.D., as Chief Medical Officer. Dr. Warner brings over 20 years of clinical development leadership experience to TYRA. He will oversee the company's clinical portfolio and join the executive management team. TYRA is developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology.
Dr. Warner's extensive experience includes 18 years at Amgen, where he led clinical development for oncology and bone disease programs. He was also recently the Chief Medical Officer at eFFECTOR Therapeutics. TYRA's CEO, Todd Harris, highlighted Dr. Warner's expertise in guiding programs from early development to global registrations as important for the company's current stage, with three potential best-in-class oncology candidates and a planned IND filing for achondroplasia later this year.
The Schall Law Firm, a national shareholder rights litigation firm, has announced an investigation into Tyra Biosciences, Inc. (NASDAQ:TYRA) for potential violations of securities laws. The inquiry focuses on whether Tyra issued false or misleading statements or failed to disclose important information to investors. Shareholders who have suffered losses are encouraged to participate in the investigation. The firm specializes in securities class action lawsuits and shareholder rights litigation.
Interested parties can contact Brian Schall of the Schall Law Firm at 310-301-3335 or through their website www.schallfirm.com for a free consultation about their rights. The press release notes that this announcement may be considered Attorney Advertising in some jurisdictions.
Tyra Biosciences (NASDAQ: TYRA) reported Q2 2024 financial results and corporate highlights. Key points include:
1. Initial results from SURF301 Phase 1 study for TYRA-300 expected in 2H 2024.
2. Preclinical proof-of-concept achieved for TYRA-300 in hypochondroplasia (HCH).
3. IND cleared for TYRA-430, an FGFR4/3 biased inhibitor for hepatocellular carcinoma.
4. Chief Medical Officer transition announced; search for external candidate underway.
5. Q2 2024 net loss of $18.7 million, compared to $13.3 million in Q2 2023.
6. Cash, cash equivalents, and marketable securities of $373.8 million as of Q2 2024, expected to fund operations through at least 2026.
Tyra Biosciences announced promising preclinical results for TYRA-300, an oral FGFR3 selective inhibitor, in treating hypochondroplasia (HCH).
Presented at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference, the data showed TYRA-300 increased long bone lengths by up to 5.03% and skull size by 5.88% in mouse models, compared to vehicle-treated mice. The results support the potential of TYRA-300 as a best-in-class agent for FGFR3-related skeletal dysplasias like HCH.
The company plans to submit an Investigational New Drug (IND) application for achondroplasia (ACH) in the second half of 2024, aiming for a Phase 2 study in pediatric ACH.
Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology firm specializing in precision medicines for FGFR biology, will participate in several investor conferences. On May 28-29, 2024, CEO Todd Harris will join a fireside chat at TD Cowen's Oncology Innovation Summit. The company will engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 5-6, 2024. Additionally, Harris will present on June 12, 2024, at the Goldman Sachs Global Healthcare Conference, with further investor meetings scheduled. Webcasts of these presentations will be available on Tyra's Investor page.
Tyra Biosciences, a clinical-stage biotechnology company, reported financial results for Q1 2024, with $382.5 million in cash and marketable securities. Recent highlights include progress on TYRA-300 in oncology and achondroplasia, new board appointments, and completion of a $200M private placement financing. The company continues to advance its pipeline and expects to report SURF301 Phase 1 initial results in 2H24.
FAQ
What is the current stock price of Tyra Biosciences (TYRA)?
What is the market cap of Tyra Biosciences (TYRA)?
